InflaRx’s (IFRX) “Buy” Rating Reiterated at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $8.00 target price on the stock.

InflaRx Trading Down 3.2 %

IFRX opened at $1.20 on Thursday. InflaRx has a 12-month low of $1.14 and a 12-month high of $5.20. The company has a market cap of $70.66 million, a price-to-earnings ratio of -1.40 and a beta of 1.26. The company’s 50 day moving average is $1.50 and its 200 day moving average is $1.54.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). As a group, analysts predict that InflaRx will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. 683 Capital Management LLC lifted its stake in shares of InflaRx by 17.5% during the 3rd quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock valued at $7,003,000 after buying an additional 350,000 shares in the last quarter. Affinity Asset Advisors LLC grew its position in shares of InflaRx by 35.3% during the third quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock worth $969,000 after purchasing an additional 84,897 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in InflaRx by 45.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 268,915 shares of the company’s stock worth $801,000 after purchasing an additional 84,178 shares in the last quarter. Alps Advisors Inc. boosted its stake in InflaRx by 109.4% in the 3rd quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after purchasing an additional 43,501 shares during the period. Finally, Raymond James & Associates grew its holdings in InflaRx by 18.5% during the 3rd quarter. Raymond James & Associates now owns 162,406 shares of the company’s stock valued at $484,000 after buying an additional 25,350 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.